Nasdaq

Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress

Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials, being conducted in multiple ulcerative colitis populations and rheumatoid arthritis, beginning in the ...
Seeking Alpha

Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress

SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients.
Nasdaq

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral IL-10 Biologic Therapeutic (AMT-101) for Inflammatory Diseases in ...

- AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue - - ...